Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0U2CB
|
|||
Former ID |
DNC011692
|
|||
Drug Name |
Ibuproxam
|
|||
Synonyms |
Ibuproxam; Ibudros; Ibuproxamum; 53648-05-8; Ibuproxam [INN]; n-hydroxy-2-(4-isobutylphenyl)propanamide; G-277; BRN 2267673; CHEMBL292707; CHEBI:76160; D,L-2-(4-Isobutylphenyl)propiohydroxamic acid; p-Isobutylhydratropohydroxamic acid; Ibuproxam (INN); D,L-N-Hydroxy-alpha-methyl-4-(2-methylpropyl)benzeneacetamide; N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide; Propionohydroxamic acid, 2-(p-isobutylphenyl)-, D,L-; Deflogon; Ibuproxamum [INN-Latin]; (S)-Ibuproxam; 73826-33-2; Ibudros (TN); EINECS 258-683-8; NSC 305528
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Respiratory disease [ICD-11: CB40] | Withdrawn from market | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C13H19NO2
|
|||
Canonical SMILES |
CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO
|
|||
InChI |
1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)
|
|||
InChIKey |
BYPIURIATSUHDW-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 53648-05-8
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:76160
|
|||
SuperDrug ATC ID |
M01AE13
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Target Info | Inhibitor | [2] |
BioCyc | Aspirin-triggered lipoxin biosynthesis | |||
Resolvin D biosynthesis | ||||
Leukotriene biosynthesis | ||||
Lipoxin biosynthesis | ||||
Aspirin triggered resolvin D biosynthesis | ||||
Aspirin triggered resolvin E biosynthesis | ||||
KEGG Pathway | Arachidonic acid metabolism | |||
Metabolic pathways | ||||
Serotonergic synapse | ||||
Ovarian steroidogenesis | ||||
Toxoplasmosis | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
WikiPathways | Vitamin D Receptor Pathway | |||
Arachidonic acid metabolism | ||||
Eicosanoid Synthesis | ||||
Selenium Micronutrient Network |
References | Top | |||
---|---|---|---|---|
REF 1 | Anti-inflammatory agents: determination of ibuproxam and its metabolite humans. Correlation between bioavailability, tolerance and chemico-physical characteristics. Arzneimittelforschung. 1980;30(9):1607-9. | |||
REF 2 | In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem. 1987 Nov;30(11):2121-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.